Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.170
-0.050 (-4.10%)
At close: Apr 22, 2026, 4:00 PM EDT
1.240
+0.070 (5.98%)
After-hours: Apr 22, 2026, 5:40 PM EDT
Celularity Employees
Celularity had 123 employees as of December 31, 2024. The number of employees increased by 3 or 2.50% compared to the previous year.
Employees
123
Change (1Y)
3
Growth (1Y)
2.50%
Revenue / Employee
$329,902
Profits / Employee
-$655,667
Market Cap
33.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 123 | 3 | 2.50% |
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | 162 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| Senti Biosciences | 34 |
| Palatin Technologies | 29 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| INmune Bio | 21 |
CELU News
- 1 day ago - Celularity Announces Closing of Transaction with NexGel - GlobeNewsWire
- 5 days ago - Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - GlobeNewsWire
- 5 weeks ago - Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - GlobeNewsWire
- 6 weeks ago - EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
- 6 weeks ago - Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - GlobeNewsWire
- 2 months ago - Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - GlobeNewsWire
- 4 months ago - Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations - GlobeNewsWire
- 4 months ago - Celularity Announces Closing of Financing Transactions - GlobeNewsWire